MAPT and Alzheimer disease: Hence, given the tight association between fluid p-tau and Aβ pathology across the AD continuum, it is difficult to establish whether increases in p-tau biomarkers (e.g., p-tau181, p-tau217 and p-tau231) are indicative of Aβ or tau deposition in the brain.